Intuitive Surgical, Inc. is an American biotechnology company that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System. The company is part of the Nasdaq-100, S&P 100 and S&P 500. As of 31 December 2021, Intuitive Surgical had an installed base of 6,730 da Vinci Surgical Systems, including 4,139 in the U.S., 1,199 in Europe, 1,050 in Asia, and 342 in the rest of the world.[2]
Intuitive Surgical first appeared on the Fortune 500 in 2024 at number 497; in 2025 the company rose to number 459 overall and ranked 43rd within the healthcare sector.[3][4]
History
The research that eventually led to the development of the da Vinci Surgical System was performed in the late 1980s by Ajit Shah and Gary Guthart at research institute SRI International